PDF(Pubmed)
Abstract：
UNASSIGNED: Lymphedema can develop during the progression of neoplastic diseases and is a devastating complication in patients with cancer receiving palliative care. This study aimed to investigate the course of treatment for lymphedema in patients receiving palliative care to assess posttreatment outcomes.
UNASSIGNED: This single-center, retrospective cohort study reviewed the maintained database of patients with lymphedema who presented to our department from January 2015 through December 2022. A combination of skin care, compression therapy, and lymphaticovenular anastomosis was used to treat lymphedema in patients with cancer receiving palliative care. The upper or lower extremity lymphedema indices, calculated based on 5 upper or 4 lower extremity circumferences and body mass index, were compared at the first and last visits.
UNASSIGNED: Of the 202 patients with lymphedema, 38 patients with 45 affected limbs (upper extremities: 11 patients, 12 limbs; lower extremities: 27 patients, 33 limbs) were included in the analysis. There were no significant changes in edema based on the upper or lower extremity lymphedema indices in the upper (P = .931) or lower extremities (P = .767) between the first and last visits. No pain relief was observed after the treatment. In the treatment differences, the rate of change in edema was -3.6 ± 10.8% for the compression garment and +5.7 ± 11.5% for the lymphaticovenular anastomosis, showing no significant difference (P = .157).
UNASSIGNED: All treatments had limited therapeutic effects, such as reduced edema and pain relief, and there were no significant differences between them.
UNASSIGNED: This single-center, retrospective cohort study reviewed the maintained database of patients with lymphedema who presented to our department from January 2015 through December 2022. A combination of skin care, compression therapy, and lymphaticovenular anastomosis was used to treat lymphedema in patients with cancer receiving palliative care. The upper or lower extremity lymphedema indices, calculated based on 5 upper or 4 lower extremity circumferences and body mass index, were compared at the first and last visits.
UNASSIGNED: Of the 202 patients with lymphedema, 38 patients with 45 affected limbs (upper extremities: 11 patients, 12 limbs; lower extremities: 27 patients, 33 limbs) were included in the analysis. There were no significant changes in edema based on the upper or lower extremity lymphedema indices in the upper (P = .931) or lower extremities (P = .767) between the first and last visits. No pain relief was observed after the treatment. In the treatment differences, the rate of change in edema was -3.6 ± 10.8% for the compression garment and +5.7 ± 11.5% for the lymphaticovenular anastomosis, showing no significant difference (P = .157).
UNASSIGNED: All treatments had limited therapeutic effects, such as reduced edema and pain relief, and there were no significant differences between them.
摘要：
■淋巴水肿可在肿瘤性疾病的进展过程中发展，并且是接受姑息治疗的癌症患者的毁灭性并发症。本研究旨在调查接受姑息治疗的患者淋巴水肿的治疗过程，以评估治疗后的结果。
■这个单中心，回顾性队列研究回顾了2015年1月至2022年12月在我们科室就诊的淋巴水肿患者的数据库.皮肤护理的组合，压迫治疗,淋巴静脉吻合术用于治疗接受姑息治疗的癌症患者的淋巴水肿。上肢或下肢淋巴水肿指数，根据5个上肢或4个下肢围和体重指数计算，在第一次和最后一次访问时进行了比较。
■在202例淋巴水肿患者中，38例患者45例患肢（上肢：11例，12条肢体；下肢：27例，分析中包括33条肢体）。在第一次和最后一次就诊之间，基于上肢或下肢淋巴水肿指数（P=.931）或下肢（P=.767）的水肿没有显着变化。治疗后没有观察到疼痛缓解。在治疗差异上,压迫衣的水肿变化率为-3.6±10.8%，淋巴静脉吻合的水肿变化率为-5.7±11.5%，差异无统计学意义(P=0.157)。
■所有的治疗都有有限的疗效，如减轻水肿和缓解疼痛，它们之间没有显著差异。
■这个单中心，回顾性队列研究回顾了2015年1月至2022年12月在我们科室就诊的淋巴水肿患者的数据库.皮肤护理的组合，压迫治疗,淋巴静脉吻合术用于治疗接受姑息治疗的癌症患者的淋巴水肿。上肢或下肢淋巴水肿指数，根据5个上肢或4个下肢围和体重指数计算，在第一次和最后一次访问时进行了比较。
■在202例淋巴水肿患者中，38例患者45例患肢（上肢：11例，12条肢体；下肢：27例，分析中包括33条肢体）。在第一次和最后一次就诊之间，基于上肢或下肢淋巴水肿指数（P=.931）或下肢（P=.767）的水肿没有显着变化。治疗后没有观察到疼痛缓解。在治疗差异上,压迫衣的水肿变化率为-3.6±10.8%，淋巴静脉吻合的水肿变化率为-5.7±11.5%，差异无统计学意义(P=0.157)。
■所有的治疗都有有限的疗效，如减轻水肿和缓解疼痛，它们之间没有显著差异。
